Eli Lilly continues its M&A spree with a $2.3 billion deal to acquire Ajax Therapeutics and its JAK2 blood cancer program, marking the pharma giant's latest deployment of GLP-1 profits. In a historic milestone, Intellia Therapeutics reported the first-ever Phase 3 success for an in vivo CRISPR gene-editing therapy in hereditary angioedema and has filed for regulatory approval. Meanwhile, Oruka Therapeutics posted promising Phase 2 psoriasis data that could position it as a future challenger to AbbVie's blockbuster Skyrizi. In a major consolidation move, Sun Pharma agreed to acquire Organon for $11.75 billion, creating a combined $12.4 billion revenue platform. The biotech IPO market also shows continued momentum as two biotechs target $180 million offerings this week.
Top Stories
Intellia Reports First Phase 3 Success for In Vivo CRISPR Therapy, Files for Approval in Hereditary Angioedema
Endpoints News and pharmaphorum report that Intellia Therapeutics achieved a historic milestone with the first-ever Phase 3 readout for an in vivo gene-editing therapy, with CRISPR-based lonvo-z dramatically reducing swelling attacks in patients with hereditary angioedema after a single dose. STAT notes the company has filed for regulatory approval following the success. This signals a watershed moment for CRISPR technology, potentially opening the door for a wave of in vivo gene-editing therapies across multiple rare diseases.
Lilly Deploys $2.3 Billion to Acquire Ajax Therapeutics and JAK2 Blood Cancer Asset
Eli Lilly announced it will pay up to $2.3 billion to acquire Ajax Therapeutics and its JAK inhibitor program targeting blood cancers, according to Endpoints News, pharmaphorum, and Pharmaceutical Executive. The deal represents Lilly's continued reinvestment of GLP-1 windfall profits into pipeline expansion, coming shortly after its Kelonia acquisition. The move suggests Lilly is building a serious oncology franchise beyond its diabetes and obesity dominance, hedging against future patent cliffs.
Sun Pharma to Acquire Organon for $11.75 Billion in Cash
Sun Pharmaceutical Industries announced an agreement to acquire Organon & Co. for $11.75 billion in cash ($14.00 per share), creating a combined entity with $12.4 billion in revenue across 150 countries, Pharmaceutical Technology reported. Organon, which was spun off from Merck & Co. in 2021 and generated $6.2 billion in revenue in 2025, brings a portfolio of more than 70 products spanning women's health, general medicines, and biosimilars. The deal is expected to close in early 2027, subject to regulatory and stockholder approvals. This signals a major consolidation play in the generics and established-brands space, with Sun Pharma nearly doubling its EBITDA and diversifying beyond its current geographic and therapeutic footprint.
Oruka Posts Promising Phase 2 Psoriasis Data, Positioning for Skyrizi Competition
Oruka Therapeutics reported that 63.5% of patients (40 of 63) achieved significant skin plaque clearance in a Phase 2 psoriasis trial, positioning its experimental drug as a potential future challenger to AbbVie's blockbuster Skyrizi, Endpoints News reported. The data suggest Oruka's differentiated mechanism could carve out market share in the crowded IL-23 inhibitor space, though Phase 3 execution and payer access will be critical hurdles.
Two Biotechs Target $180 Million IPOs as Market Momentum Builds
Seaport and Hemab are each seeking approximately $180 million in initial public offerings this week to advance programs in depression and clotting disorders, respectively, according to Fierce Biotech. The dual offerings represent the latest evidence of a resurgent biotech IPO window after years of drought. Worth watching because sustained IPO activity could unlock capital for earlier-stage companies that have been starved of funding.
TrumpRx Prescription Drug Initiative Signs Deals With 86% of Branded Drug Market
The TrumpRx initiative has secured agreements with nearly every major drugmaker, covering 86% of the branded pharmaceutical market, though questions remain about whether prices are actually falling for most Americans, Forbes reports. Analysis suggests benefits may be concentrated among specific patient populations rather than broadly distributed across the healthcare system. This signals potential political risk if real-world pricing impact fails to match the administration's rhetoric ahead of election cycles.
What to Watch
- Intellia regulatory timeline — The company's filing represents the first-ever CRISPR in vivo therapy submission; FDA decision timing and label scope could set precedents for the entire gene-editing sector.
- Lilly's oncology buildout — With Ajax following Kelonia, watch whether Lilly pursues additional tuck-in deals or larger transformational M&A to establish leadership beyond metabolic disease.
- Oruka's Phase 3 design — Phase 2 efficacy must translate to pivotal trials with head-to-head or non-inferiority designs against entrenched IL-23 competitors to secure meaningful market access.
- IPO window sustainability — Back-to-back $180M offerings test whether investor appetite extends beyond mega-rounds for late-stage assets to include earlier platforms and novel modalities.
- Sun-Organon integration — With closing expected in early 2027, watch for regulatory scrutiny in key markets and whether the combined entity's 2.3× net debt/EBITDA leverage ratio limits further dealmaking in the near term.
Market Snapshot
- CRISPR validation milestone: Intellia's Phase 3 success could accelerate investor confidence in the broader gene-editing space, potentially benefiting peers like Editas, Beam, and Verve with pipeline catalysts ahead.
- GLP-1 cash redeployment: Lilly's $2.3B Ajax deal underscores how obesity drug profits are reshaping competitive dynamics across oncology, neuroscience, and rare disease M&A landscapes.
- Dermatology competition intensifies: Oruka's 63.5% Phase 2 response rate in psoriasis adds pressure on established IL-23 franchises from AbbVie, J&J, and others to demonstrate differentiation or risk commoditization.